We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

152 hedge funds and large institutions have $398M invested in Sciclone Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $210K | Put options by funds: $136K

35% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 46

5% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 21

1% more funds holding

Funds holding: 151 → 152 (+1)

3.58% less ownership

Funds ownership: 79.73% → 76.15% (-3.6%)

17% less capital inflows, than outflows

Capital inflows: $67.7M | Capital outflows: $81.2M

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
152
Holders Change
+1
Holders Change %
+0.66%
% of All Funds
4.04%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
22
Increased
62
Reduced
46
Closed
21
Calls
$210K
Puts
$136K
Net Calls
+$74K
Net Calls Change
-$1.2M

SCLN Hedge Fund Activity: Q3 2016 in Review

152 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q3 2016, worth a combined $398M — down 23% from $520M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SCLN positions and 21 closed out — a net gain of 1 holder — while 62 added to existing stakes and 46 trimmed.

The largest buyer was Numeric Investors, adding an estimated $22.7M. The largest seller was Franklin Resources, cutting an estimated $35.4M.

  • 152 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q3 2016, up from 151 in Q2 2016.
  • Funds reported $398M of Sciclone Pharmaceuticals stock for Q3 2016, down 23% quarter-over-quarter.
  • 22 funds opened new Sciclone Pharmaceuticals positions in Q3 2016 and 21 closed out, a net change of +1 holder.
  • The largest Sciclone Pharmaceuticals buyer in Q3 2016 was Numeric Investors, an estimated $22.7M added.
  • The largest Sciclone Pharmaceuticals seller in Q3 2016 was Franklin Resources, an estimated $35.4M sold.

Based on aggregated 13F filings for Q3 2016.